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Objectives: To evaluate the patient characteristics and health care burden asso-
ciated with chronic obstructive pulmonary disease (COPD) in the U.S. Medicare 
population. MethOds: COPD patients were identified (International Classification 
of Disease, 9th Revision, Clinical Modification [ICD-9-CM] codes: 491.xx, 492.xx and 
496.xx) using U.S. national Medicare claims from 01JAN2007 to 31DEC2010. The first 
diagnosis date was designated as the index date. Patients were required to: a) be age 
≥ 65 years on the index date; b) have continuous medical and pharmacy benefits for 12 
months pre-index date (baseline period); c) have continuous enrollment for 12 months 
post-index date (follow-up period), unless there was earlier evidence of death; and d) 
have no COPD diagnosis pre-index date. The outcomes of interest included medication 
use, including a long-acting beta agonist (LABA) or LABA/inhaled corticosteroid (ICS) 
combination, mortality and health care resource utilization and costs. Results: A 
total of 543,249 COPD patients were identified. Patients were, on average, age 78 years. 
Most patients were white (94%) and resided in the South U.S. region (41%). The average 
Charlson Comorbidity Index score was 3.23, and hypertension (67%), diabetes (28%), 
congestive heart failure (21%) and chronic pulmonary disease (20%) were the most 
frequently diagnosed comorbidities. A 13.82% mortality rate was observed during 
the first year of the follow-up period. Post-index LABA medications, including arfo-
moterol (0.55%), formoterol (0.25%) and salmeterol (0.32%) were prescribed to 1.10% 
of the population. Identified LABA/ICS combinations included budesonide/formoterol 
(1.97%) and fluticasone/salmeterol (10.02%). High health care resource utilization was 
encountered for Medicare carrier (99.40%), pharmacy (90.27%), outpatient (76.52%) 
and inpatient visits (48.83%). The main cost drivers were inpatient ($10,645), Medicare 
carrier ($4,888), outpatient ($3,322) and skilled nursing facility ($2,695) costs, resulting 
in $25,397 in total health care costs. cOnclusiOns: U.S. Medicare patients have a 
high COPD-related health care burden.
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Objectives: The aim of this study was to examine the association between 
inhaled bronchodilators and the utilization of healthcare services in newly-diag-
nosed COPD patients using a nationalwide health insurance administrative data-
bases. MethOds: The Taiwan National Health Insurance Research Databases were 
used. Participants ≧ 40-years-old who had not been diagnosed with COPD between 
2006 and 2007 but were diagnosed and prescribed COPD medications in 2008 were 
recruited as newly diagnosed COPD patients. Patients were categorized into three 
groups depending on their medications use, an inhaled long-acting bronchodila-
tor (ILA-B), an inhaled short-acting bronchodilator (ISA-B) and an oral respiratory 
medication (ORM) group. The risk of COPD emergency department visits, hospi-
talization and healthcare costs were compared among cohorts during 1 year of 
follow-up. Results: A total of 13,181 newly-diagnosed COPD patients with a mean 
age of 65.2 years, among which 8,055 (60.7%) were men, were included in the study. 
ED visits and hospitalization were associated with ISA-B cohort, male gender, older 
age, copayment exemptions, tertiary healthcare institutions visits, non-pulmonary 
specialist physicians and higher comorbidities. Multivariate analysis showed that 
the ISA-B cohort was associated with more ED visits, recurrent ED visits, hospitaliza-
tions and rehospitalizations (adjusted ORs [95% confidence intervals] = 5.06 [3.46, 
7.41], 3.98 [2.08, 7.58], 1.59 [1.18, 2.21], and 1.42 [1.19, 2.18], respectively) compared 
with the ILA-B cohort. The ILA-B cohort incurred significantly higher adjusted phar-
macy costs per patient per year by $165 (95% CI: $97, $233; P< 0.001) vs the ISA-B 
cohort, whereas adjusted medical costs per patient per year were significantly 
lower in the ILA-B cohort vs the ISA-B cohort ($348 vs $564; P< 0.001). The total 
yearly adjusted costs per patient, as a result, did not differ significantly between 
this two cohorts. cOnclusiOns: Initiation of Inhaled long-acting bronchodilator 
treatment was associated with better clinical and economic outcomes compared 
to inhaled short-acting bronchodilator in newly-diagnosed COPD patients in real-
life clinical practice.
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Objectives: Tiotropium (tio) is a well-established bronchodilator, LAMA (long-acting 
anticholinergic), for the treatment of moderate to very severe COPD. Clinical evidence 
from the SPARK trial suggests that tio is superior to glycopyrronium (gly) in prevent-
ing severe exacerbations. This study assessed the cost-effectiveness of tio versus gly 
making use of this new clinical evidence. MethOds: A Markov cohort model was 
populated with efficacy data from the UPLIFT and SPARK trials and cost and epidemio-
logical data relevant for each country. Treatment efficacy was modelled as improve-
ments in lung function, quality of life and as a lowering of the risk of exacerbations. 
The two interventions were assumed to be equally efficacious in terms of overall 
lung function, FEV1 (GLOW2 and SPARK trials). The relative efficacy of preventing 
exacerbations differed based on data from SPARK. Outcomes were simulated over an 
approximate life time horizon of 35 years, starting from an age of 65 years. Results: 
The base case analysis showed that patients treated with tio gained CAN: 0.23, SWE: 
0.24, UK: 0.25, QALYs compared to gly at an incremental cost of -955 (C$), 3,224 (SEK), 
-164 (£). For CAN and UK the analysis found tio to be dominating gly, while the Swedish 
analysis showed a cost per QALY gained of SEK 13,621. The results were mainly driven 
by the relative risk of severe exacerbations found in SPARK (RR: 1.43 CI 1.05-1.97, 
P 0.025). cOnclusiOns: The results from this study show that tio adds benefits 
and savings in terms of QALYs and costs compared to gly monotherapy in high-risk 
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Objectives: To present simple, objective, and customizable cost estimation formu-
las to compare per-attack treatment costs of four recently FDA-approved Hereditary 
Angioedema (HAE) products. MethOds: Products developed for small orphan 
disease populations such as hereditary angioedema (HAE) are predictably costly. 
Comparing treatment costs among new HAE therapies is complicated by differences 
in dosing recommendations and re-dosing probabilities. We propose a simple cost 
estimation formula that factors in the non-static variables of body weight and re-
dosing likelihood per attack based on official prescribing recommendations and 
published clinical study data. Other administrative or indirect costs were not fac-
tored into the formulas. Results: Formulas were developed that allow insertion 
of local acquisition costs for any of the HAE products, according to the quantity of 
vials or syringes required for initial dosing. A weighted percentage of the cost of the 
initial dose was added to determine the total cost, factoring in the anticipated need 
for re-dosing. For products having more than one published re-dosing frequency, 
the lowest reported frequency was used as a conservative approach. Specific cost 
estimation formulas address three theoretical patient weight categories: ≤ 40 kg (to 
reflect small adults or pediatric patients), a standard 75 kg adult, and obese patients 
weighing between 100-125 kg. cOnclusiOns: While therapy choices in HAE should 
be primarily driven by clinical factors and patient preferences, cost of treatment can 
be an important consideration if multiple options are considered equally appropri-
ate. The formulas presented provide a simple, objective means of quickly comparing 
direct product costs for treating an HAE attack using local pricing figures.
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Objectives: Community-acquired pneumonia (CAP) is a leading cause of hospi-
talization in the US and is associated with substantial healthcare costs. The most 
commonly administered regimen for hospitalized patients, guideline-indicated intra-
venous azithromycin 500mg/ceftriaxone 1g (azi/ceft), is not available in identical oral 
formulation, requiring patients to switch regimen and potentially class when suffi-
ciently improved for oral treatment (oral switch). The incremental cost and resource 
utilization associated with this requirement has not been fully characterized. This 
study characterizes the incremental burden of a regimen lacking identical all-oral 
formulation. MethOds: Inpatient stay data from the Truven Health Marketscan® 
Hospital Drug Database were used in this analysis. CAP inpatients treated with azi/
ceft were compared to those treated with intravenous levofloxacin 750mg (levo, a 
fluoroquinolone), the most commonly used regimen with an all-oral option. As previ-
ous studies have shown higher adverse event (AE) rates in fluoroquinolone patients, 
only patients (azi/ceft or levo) who remained on their treatment until oral switch 
were studied. Total charges, length of stay (LOS), and length of IV treatment (LOIV) 
were compared using multivariate regression models controlling for observed patient 
characteristics. Results: In the sample (N= 33,284), predicted average charges for azi/
ceft patients were $3,535 greater than charges for levo patients, with increased LOS 
of 0.33 days and LOIV of 0.65 days (all p< 0.0001). 28.3% of azi/ceft patients added an 
additional treatment class, versus 5.1% of levo patients. Characteristic comparisons 
showed that azi/ceft patients were older (66.4 vs. 64.7 years), but similar in health 
index (1.49 vs. 1.45) and AE rate (35.3% vs. 35.8%). cOnclusiOns: Use of azi/ceft, the 
most common antibiotic regimen for hospitalized CAP patients but one that lacks 
an identical all-oral formulation, is associated with increased LOIV, LOS and cost. 
Efficacious alternatives with similar (or better) adverse event profiles and an all-oral 
formulation may yield cost and resource use savings.
PRS22
Out-Of-POcket exPenSeS fOR cOPd PatientS in a thiRd level hOSPital
Martínez- Briseño D., Fernández-Plata R., García-Sancho C., Cano-Jiménez D.,  
Sansores-Martínez R., Ramíres-Venegas A., Casas-Medina G.
National Institute of Respiratory Diseases, Mexico City, Mexico
Objectives: Chronic Obstructive Pulmonary Disease (COPD) is a main worldwide 
cause of morbidity and mortality. COPD prevalence in 40 years or older people is 7.8% 
in Mexico City. However, there is no information about direct cost of COPD patients 
in Mexico. This study estimated direct costs of COPD from patient perspective in a 
third level hospital. MethOds: We conducted an interview at each visit by patients 
from august 2013 to July 2014 in a third level hospital. The diagnosis was carried out 
by a pulmonologist according to GOLD criteria. Information about direct and indirect 
costs was collected. Mean (SD) of annual total cost, medical consultation, clinical test, 
drugs, oxygen, transportation, gasoline and food were estimated for outpatients with 
at least one year of diagnosis and stratifying by severity. Costs were transformed in 
US Dollars of 2014. Results: We interviewed 482 outpatients. Patients were classified 
as: mild (n= 36), moderate (n= 137), severe (n= 76) and very severe (n= 233). Mean (SD) 
of age and diagnostic time were 72.4 (9.1) and 5.8 (4.2) years, respectively; and 257 
(53.2%) were men. Annual total costs for mild, moderate, severe and very severe were 
$915.3, $1214.3, $1382.6 and $1595.1, respectively. Drugs (74.0%), oxygen (19.5%) and 
transportation (1.8%) were the main categories of total costs. Less than 9% of patients 
can afford oxygen. cOnclusiOns: According to total cost, severity is positively corre-
lated with the amount of out-of-pocket expenses. Oxygen is accessible to few patients.
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ing to the CONAPO’s Mexican population projection with 40 years old or over, the 
prevalence of the COPD in Mexico (PLATINO study) and the proportion of people 
that uses biomass for cooking. A deterministic sensitivity analysis was performed 
in both cases. Results: Annual cost of glycopyrronium bromide monotherapy was 
US$265.27 and for tiotropium bromide monotherapy was US$242.30 in one year 
horizon with a percent difference of 10.16% per patient. The budget impact costs 
in the first year were $287,409,746.74 and $262,527,500.25 for tiotropium bromide 
monotherapy and glycopyrronium bromide monotherapy respectively, with savings of 
9.5% using glycopyrronium bromide monotherapy. cOnclusiOns: Glycopyrronium 
bromide monotherapy is less costly than tiotropium bromide monotherapy which 
shows us that is possible to achieve cost-savings with at least the same clinical ben-
efit from the perspective of the Mexican public health system, in specific from IMSS. 
*IMSS (Mexican Institute of Social Security) *CONAPO (National Council of Population) 
*Exchage rate 14.55 MXN
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Objectives: To estimate annual loss of productivity costs attributable to being over-
weight or having obesity in working US adults with asthma patients. MethOds: This 
study applied a cross-sectional design using the 2008-2012 Medical Expenditure Panel 
Survey (MEPS). Asthma patients (18-64 years old) were identified by self-reported 
diagnosis, Clinical Classification Codes of 128, or ICD-9-CM code of 493. To investigate 
the impact of being overweight or having obesity, patients were classified as normal-
weight (18.5≤ BMI< 25), overweight (25≤ BMI< 30), and obese (BMI≥ 30). Productivity 
loss costs, which were measured based on missed work days due to illness or injury 
for one year and the hourly wage, were estimated using a two-part model to adjust 
for patients with zero costs. To estimate the productivity loss costs attributable to 
being overweight or obese, each group of costs was estimated by assuming every-
body is overweight or obese; these costs were then re-estimated by assuming eve-
rybody was normal, and the mean difference between the two estimated costs was 
calculated. All costs were converted to 2013 US dollars using the Consumer Price 
Index (CPI). Results: Among a total of 5,391 working adults with asthma, preva-
lence of normal-weight was 28.9%, overweight 31.4%, and obese 39.7%. Annual aver-
age productivity loss costs for normal, overweight, and obesity in asthma patients 
were $360(95%CI:$297-$423), $461(95%CI:$374-$548), and $753(95%CI:$620-$886) per 
patient, respectively. Among patients with asthma who had loss of productivity costs, 
those with obesity had 1.33 times greater productivity loss costs than normal-weight 
patients. Thus, the productivity loss costs attributable to being overweight or obesity 
in working asthma patients were estimated at $24(95%CI:$24-$25) or $190(95%CI:$184-
$196) per patient per year, respectively. cOnclusiOns: The loss of productivity costs 
among US asthma patients is substantial, which is only further amplified by the 
presence of obesity. This study highlights the importance of obesity control in order 
to reduce burden of asthma treatment and enhance productivity.
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Objectives: Chronic urticaria (or chronic hives) can be inducible or spontaneous 
(CSU). Data supporting the impact of CSU on patients and comparisons with other 
dermatological diseases are scarce. This study evaluated economic burden associated 
with CSU relative to psoriasis (PsO) among the adults in 5 European (5EU) countries 
and United States (US). MethOds: Data from diagnosed chronic hives (used as proxy 
for CSU) and PsO patients collected in the National Health and Wellness Survey (2010-
11 & 2013) for 5EU and (2010-12) for US were used for this retrospective, cross-sectional 
analysis. Outcome measures included the Work Productivity and Activity Impairment 
questionnaire (WPAI) and self-reported healthcare use in prior 6 months. Bivariate 
analysis (t-tests for continuous and chi-square for categorical variables) was used to 
compare patients with CSU vs. PsO. Results: Study included 1,516 patients with CSU 
(769 EU; 747 US) and 12,964 patients with PsO (7,857 EU; 5,107 US). In EU, employed 
CSU patients reported higher absenteeism (10.5% vs. 6.8%), presenteeism (27.4% vs. 
20.5%), overall work impairment (32.6% vs. 24.6%) and activity impairment (39.5% vs. 
30.5%) compared to PsO patients. Similarly, US CSU patients reported higher WPAI 
parameters (8.6% vs. 4.6%), (25.6% vs. 19.1%), (28.9% vs. 21.4%) and (38.9% vs. 31.2%), 
respectively (p< 0.01 for all). CSU patients had more hospitalizations (0.43 vs. 0.17), 
and more visits to ER (0.75 vs. 0.25), physician (3.08 vs. 2.52) and allergist (0.21 vs. 0.06) 
compared to PsO patients (p< 0.001 for all) in EU. Similarly, US CSU patients showed 
more hospitalizations (0.26 vs. 0.15), ER visits (0.42 vs. 0.25), physician (1.46 vs. 1.24) 
and allergist (0.25 vs. 0.09) visits than PsO patients (p< 0.05 for all). cOnclusiOns: 
This analysis of patient reported data show that CSU has a similar or even higher 
economic burden than PsO patients in both EU and US patient population.
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patients. As the results were mainly driven by the lower rates of severe exacerbations 
in the tio arm, this highlights the importance of exacerbations when assessing cost-
effectiveness in moderate to very severe COPD. Overall, a broader range of evidence 
parameters should be considered in economic modelling of COPD.
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Objectives: Patients with severe refractory asthma experience persistent symptoms 
despite adhering to guideline-based therapies, and they utilize a disproportionate 
share of asthma healthcare resources. Several new treatments are available that 
have been shown to improve symptoms and quality of life in patients with refrac-
tory asthma. The objective of this study was to determine the cost effectiveness of 
primary medical treatment strategies for severe refractory asthma, including biologic 
therapies and follow-on bronchial thermoplasty. MethOds: A decision tree analytic 
model to investigate the comparative effect of two biologic therapies and follow-on 
bronchial thermoplasty on asthma exacerbation-related costs and utilities. Endpoints 
of interest were ER visits, hospitalizations, death, and direct healthcare costs. Base-
case inputs were taken from prior literature or assumed as necessary. We used a 
U.S. healthcare perspective, a hypothetical cohort of 10,000 adult refractory asthma 
patients, an annual cycle, and 10-year time horizon to construct our model. Results: 
Among patients who respond to biologic treatment, the addition of bronchial thermo-
plasty was not cost-effective. Mepolizumab without bronchial thermoplasty was the 
most cost-effective option for biologics responders, with a 10-year-per-patient cost of 
$116,776 and 5.46 QALYs gained (ICER $21,388). Among patients who do not respond 
to biologic treatment, bronchial thermoplasty is a cost effective treatment option 
($33,161/QALY). Sensitivity analysis shows that the model is reactive to changes in 
medication cost; a 10% increase in mepolizumab cost results in only omalizumab 
alone or with bronchial thermoplasty being cost-effective. cOnclusiOns: In a 
hypothetical cohort of refractory asthma patients over a 10-year period, it is not cost 
effective to add bronchial thermoplasty to biologic responders’ therapy; however, in 
biologic non-responders, bronchial thermoplasty remains a cost effective add-on 
treatment option. Future studies should incorporate long-term efficacy inputs of 
bronchial thermoplasty and real-world mepolizumab cost data to address assump-
tions necessary due to limited data currently availability for these newer therapies.
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bAcKGROunds: Smoking cessation medications have been shown to yield higher 
success rates and sustained abstinence when compared to unassisted quit attempts. 
Although unassisted smoking cessation is still common in Japan, various treat-
ments, including nicotine replacement therapy (NRT) and varenicline, can be 
covered by the health insurance system. Objectives: To compare the health and 
economic consequences in Japan of using pharmacotherapy to support smoking ces-
sation with unassisted attempts and the current mix of strategies used. MethOds: 
A discrete event simulation model was developed, which included multiple quit 
attempts and relapses. The risk of developing smoking-related diseases was esti-
mated based on the duration of smoking abstinence. Data collected from a survey 
conducted in Japan was used to determine the interventions selected by smokers 
initiating a quit attempt, along with the time between multiple quit attempts. The 
analyses were conducted from healthcare payers’ perspective, with supplemental 
analyses in which productivity losses due to smoking-related diseases were esti-
mated. Time horizon was set to lifetime. Results: Using pharmacotherapy (NRT 
or varenicline) to support quit attempts proved to be dominant when compared 
with unassisted attempts or the current mix of strategies (most are unassisted). If 
varenicline is always chosen as the first choice for a quit attempt, it would save JPY 
206,100 and prolong 0.08QALY per smoker over a lifetime horizon, compared to cur-
rent mix of strategies. The greatest cost saving was observed for the smokers aged 
from 40 to < 50 years. cOnclusiOns: Increased utilization of smoking cessation 
pharmacotherapy to support quit attempts is estimated to be cost-saving, as well 
as to improve health outcomes of the many smokers who want to quit.
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Objectives: To perform a cost-minimization analysis and budget impact of gly-
copyrronium bromide monotherapy versus tiotropium bromide monotherapy as a 
maintenance treatment in adult patients with moderate to severe chronic obstructive 
pulmonary disease (COPD) from the perspective of the Mexican public healthcare 
system. MethOds: Using data from GLOW 5 study, it was established the equiva-
lence of safety and efficacy of glycopyrronium bromide monotherapy and tiotropium 
bromide monotherapy, so it is evaluated the annual costs of each therapy to establish 
the cost-savings with glycopyrronium bromide monotherapy. COPD drug cost was 
estimated for one year in the cost-minimization analysis, using local prices for public 
healthcare institutions (IMSS). It was developed a 5 year horizon budget impact from 
the perspective of the Mexican public healthcare system with an annual discount 
rate of 5%. The total population used for the budget impact was calculated accord-
